26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
21 September 2020BioPharm America™ 2020 Digital —13th Annual International Partnering ConferenceFor this year’s digital event, BioPharm America will focus on Innovation and Investing, with the added collaboration of a number…read more >>
25 August 2020ChinaBio ® Partnering Forum 2020 DigitalChinaBio® Partnering Forum is the largest and most productive China-focused life science partnering event. To be held as a digital…read more >>
24 August 20204th AMR Conference Novel Antimicrobial & AMR Diagnostics – Delivered DigitallyIn view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic, we have decided to implement…read more >>
13 July 2020Curious2020 – Future Insight Virtual EventThis event will feature three key global initiatives to support further advancement in science & technology, solving the challenges of…read more >>
09 July 2020REVIVE Webinar: The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case studyIn this webinar, Anand Anandkumar and Kamini Walia will discuss: - Why is India one of the hotbeds of the…read more >>
09 July 2020Webinar: Antimicrobial Resistance (AMR): Phenotypic vs. Target-Based ScreeningThe webinar intends to motivate a revision of the way we feed the research funnel with new ideas, new biology…read more >>
09 July 2020Global Launch – Virtual Event from Berlin: NEW INITIATIVE TAKES ON THE ANTIBIOTIC INNOVATION CHALLENGEThe world is losing its most powerful tool in healthcare: antibiotics. We need to take action now. Organized by IFPMA,…read more >>
30 June 2020REVIVE Webinar: Clinical development of antimicrobials – Phase 1 development challengesSpeaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)read more >>
25 June 2020REVIVE Webinar: Putting children first in the fight against antibiotic resistanceSpeakers: - Dr Christina Obiero, co-investigator for GARDP fosfomycin clinical trial in Kilifi, Kenya - Dr Manica Balasegaram, Executive Director,…read more >>
